Brief: Eiger Biopharmaceuticals Announces Complete Enrollment Of Late-Stage Study Investigating Oral Agent, Lonafarnib, In Hepatitis Delta Virus
01/11/2021 12:21
Nov 1 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES COMPLETE ENROLLMENT OF
D-LIVR, THE LARGEST PHASE 3 STUDY IN HEPATITIS DELTA VIRUS
(HDV), INVESTIGATING LONAFARNIB, THE ONLY ORAL AGENT IN
DEVELOPMENT FOR HDV
Source text for Eikon: ID:nPn3MRSpNa
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview